Video

Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer

Author(s):

Urology Times staff

“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection. Salami is an assistant professor of urology at the University of Michigan, Ann Arbor.

      Related Videos
      Paul Sieber, MD, on the future of genetic testing in prostate cancer
      Paul Sieber, MD, on the future of genetic testing in prostate cancer
      Daniel Kwon, MD, answers a question during a Zoom video interview
      Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
      Tim Richardson, MD, on genetic testing in the era of targeted therapies
      Tim Richardson, MD, on genetic testing in the era of targeted therapies
      DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
      Discussing germline testing for prostate cancer with veterans
      Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
      Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
      Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
      Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
      DNA molecules | Image Credit: © vitstudio - stock.adobe.com
      Germline testing study’s implications for veteran access to prostate cancer treatments
      Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
      Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
      Daniel Kwon, MD, answers a question during a Zoom video interview
      Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
      Randy A. Vince Jr, MD, MS, answers a question during a Zoom video interview
      Dr. Vince on evaluation of prostate cancer polygenic risk scores
      Related Content
      Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
      February 25th 2025

      Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

      Hannah Clarke
      Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
      Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
      January 29th 2025

      Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

      Hannah Clarke
      WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
      Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
      January 22nd 2025

      Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

      Hannah Clarke
      "[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
      3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
      December 24th 2024

      Quiz: CUA guidelines on specimen and timing considerations with genetic testing

      Patrick Campbell
      Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
      NCCN reaffirms Prolaris’ prognostic value in prostate cancer
      December 18th 2024

      NCCN reaffirms Prolaris’ prognostic value in prostate cancer

      Hannah Clarke
      The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
      DNA helix | Image Credit: © Siarhei - stock.adobe.com
      December 17th 2024

      Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer

      Patrick Campbell
      Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer.
      © 2025 MJH Life Sciences

      All rights reserved.